BlueMountain Capital Management LLC raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.6% during the second quarter, Holdings Channel reports. The fund owned 19,141 shares of the company’s stock after buying an additional 1,348 shares during the period. BlueMountain Capital Management LLC’s holdings in IDEXX Laboratories were worth $4,172,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. FDx Advisors Inc. acquired a new stake in IDEXX Laboratories in the 1st quarter valued at $210,000. Wells Fargo & Company MN grew its stake in shares of IDEXX Laboratories by 15.1% during the first quarter. Wells Fargo & Company MN now owns 615,973 shares of the company’s stock valued at $117,891,000 after acquiring an additional 80,947 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in shares of IDEXX Laboratories by 13.3% during the first quarter. Daiwa Securities Group Inc. now owns 2,945 shares of the company’s stock valued at $564,000 after acquiring an additional 346 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of IDEXX Laboratories by 18.6% during the first quarter. SG Americas Securities LLC now owns 10,860 shares of the company’s stock valued at $2,078,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Mackay Shields LLC acquired a new stake in shares of IDEXX Laboratories during the first quarter valued at about $2,810,000. Institutional investors and hedge funds own 91.19% of the company’s stock.

IDXX has been the subject of several recent analyst reports. BidaskClub upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Zacks Investment Research downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, June 15th. Credit Suisse Group raised their target price on IDEXX Laboratories from $209.00 to $228.00 and gave the company an “outperform” rating in a research note on Friday, June 1st. Stifel Nicolaus raised their target price on IDEXX Laboratories from $225.00 to $260.00 and gave the company a “buy” rating in a research note on Tuesday, July 10th. Finally, Piper Jaffray Companies raised their target price on IDEXX Laboratories to $236.00 and gave the company an “overweight” rating in a research note on Wednesday, August 1st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. IDEXX Laboratories currently has an average rating of “Buy” and a consensus price target of $244.00.

In related news, Chairman Jonathan W. Ayers sold 30,000 shares of IDEXX Laboratories stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $245.50, for a total value of $7,365,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jonathan W. Ayers sold 7,000 shares of IDEXX Laboratories stock in a transaction dated Thursday, August 23rd. The stock was sold at an average price of $247.33, for a total value of $1,731,310.00. The disclosure for this sale can be found here. Insiders sold 70,129 shares of company stock valued at $17,159,219 over the last quarter. Insiders own 2.56% of the company’s stock.

Shares of IDEXX Laboratories stock opened at $242.55 on Friday. The company has a debt-to-equity ratio of -14.77, a current ratio of 0.96 and a quick ratio of 0.73. The stock has a market cap of $21.27 billion, a PE ratio of 73.95, a price-to-earnings-growth ratio of 2.25 and a beta of 0.64. IDEXX Laboratories, Inc. has a 1-year low of $146.09 and a 1-year high of $256.22.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Wednesday, August 1st. The company reported $1.23 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.06. The company had revenue of $580.75 million during the quarter, compared to the consensus estimate of $574.68 million. IDEXX Laboratories had a negative return on equity of 703.80% and a net margin of 14.50%. The company’s revenue was up 14.1% on a year-over-year basis. During the same period last year, the firm earned $0.87 earnings per share. analysts predict that IDEXX Laboratories, Inc. will post 4.18 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

See Also: Growth Stocks

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.